Cynata Therapeutics Ltd (ASX:CYP) has been granted a further patent covering aspects of its proprietary Cymerus™ stem cell platform by the U.S. Patent and Trademark Office (USPTO).
The patent covers certain proprietary methods relating to the platform’s ability to efficiently manufacture mesenchymal stem cells (MSCs) at scale for therapeutic use.
The patent is owned by the University of Wisconsin–Madison’s Wisconsin Alumni Research Foundation (WARF) and is among the intellectual property licensed exclusively from WARF to Cynata.
The granting of this patent follows the granting of Orphan Drug Designation for Cynata’s lead product, CYP-001, by the US FDA for the treatment of acute graft versus host disease (GvHD).
An Orphan Drug is a therapeutic agent used for the prevention, diagnosis or treatment of a rare disease or condition that affects fewer than 200,000 people in the USA #cynatatherapeutics #stemcells #market #technology pic.twitter.com/jbxMfxcJFy
— Cynata Therapeutics (@cynatastemcells) April 9, 2018
CYP-001 is the lead mesenchymal stem cell (MSC) product manufactured using Cynata’s proprietary Cymerus platform manufacturing technology.
Once a product has been granted Orphan Drug Designation by the FDA, the sponsor or manufacturer of that product can take advantage of commercially significant incentives.
New patent strengthens Cynata’s comprehensive patent portfolio
Cynata chief executive Dr Ross Macdonald said: “We are delighted that the USPTO has granted this additional patent around our core Cymerus technology
“This further strengthens Cynata’s comprehensive patent portfolio and supports our unique technology that enables the scalable manufacture of consistent, high-quality MSC therapeutic products to treat a range of prevalent and devastating diseases worldwide”
The inventors named on the patent are Dr Gene Uenishi and Professor Igor Slukvin. Professor Slukvin is a founder, advisor and major shareholder of Cynata.